Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect

In the setting of hematopoietic stem cell transplantation (HSCT), Rituximab (RTX) is used for the treatment and prevention of EBV-associated post-transplantation lymphoproliferative disease or autoimmune phenomena such as autoimmune hemolytic anemia (AIHA). Persistent hypogammaglobulinemia and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott de Bruin, Lisa M., Pico-Knijnenburg, Ingrid, van Ostaijen-ten Dam, Monique M., Weitering, Thomas J., Berghuis, Dagmar, Bredius, Robbert G. M., Lankester, Arjan C., van der Burg, Mirjam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649739/
https://www.ncbi.nlm.nih.gov/pubmed/37958995
http://dx.doi.org/10.3390/ijms242116012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649739/
https://www.ncbi.nlm.nih.gov/pubmed/37958995
http://dx.doi.org/10.3390/ijms242116012

Ejemplares similares